Product Profiles: Depression - Next generation viesfor second-line patients                                      Phone:   ...
Phone: +44 20 8123 2220                                                                                        http://mark...
Phone: +44 20 8123 2220                                                                               http://marketpublish...
Phone: +44 20 8123 2220                                                                               http://marketpublish...
Phone: +44 20 8123 2220                                                                               http://marketpublish...
Phone: +44 20 8123 2220                                                                                                   ...
Upcoming SlideShare
Loading in …5
×

Product Profiles: Depression - Next generation vies for second-line patients

628 views

Published on

Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.

Published in: Education, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
628
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Product Profiles: Depression - Next generation vies for second-line patients

  1. 1. Product Profiles: Depression - Next generation viesfor second-line patients Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com http://marketpublishers.com
  2. 2. Phone: +44 20 8123 2220 http://marketpublishers.comProduct Profiles: Depression - Next generation vies for second-linepatientsDatamonitorDate: Jun, 2011Pages: 221Price: US$ 11,400.00ID: P9BC1E6E625ENIntroductionPatents for the current market-leading depression brands are due to expire in the major markets between2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in thisharsh environment, new antidepressants must be sufficiently differentiated from conventional monoamineneurotransmitter reuptake inhibitors.Features and benefits Understand Datamonitor’s independent appraisal of marketed brands and key pipeline agents indicated for treating depression. Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes. Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data. Understand how marketed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists. Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.HighlightsDatamonitor’s physician survey reveals that psychiatrists perceive Forest’s and Lundbeck’s selectiveserotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superiorefficacy and tolerability profile to other antidepressant brands.Valdoxan (agomelatine; Servier/Novartis) and several pipeline antidepressants are poised to usurpLexapro, following its loss of market exclusivity, and become the most attractive depression brands.Forest’s Viibryd (vilazodone) has the hallmarks of a new blockbuster – a novel mode of action, favorabletolerability, and the marketing prowess of Forest. Viibryd will be well received due to its good tolerability,although commercial success comparable to Lexapro will be unattainable as more innovative competitordrugs near the US market.Your key questions answered What is the gold-standard drug for depression? How are marketed brands positioned in the depression treatment algorithm? Which are the most likely drugs to emerge from the pipeline and how will they impact the way depression is treated? What are the comparative strengths and weaknesses of the key depression brands and pipeline candidates?Product Profiles: Depression - Next generation vies for second-line patients 2
  3. 3. Phone: +44 20 8123 2220 http://marketpublishers.comTable of ContentExecutive SummaryStrategic scoping and focusDatamonitor key findingsRelated reportsOVERVIEWCatalystSummaryMARKET DEFINITION AND OVERVIEWProduct overviewMARKETED PRODUCT PROFILESLexapro (escitalopram; Forest/Lundbeck) Drug profile Development overview SWOT analysis Product positioning Physicians perceptions of Lexapro Clinical and commercial attractivenessEffexor XR (venlafaxine extended release; Pfizer) Drug profile Development overview SWOT analysis Product positioning Clinical and commercial attractivenessPristiq (desvenlafaxine; Pfizer) Drug profile Development overview SWOT analysis Product positioning Physicians perceptions of Pristiq Clinical and commercial attractivenessCymbalta (duloxetine; Eli Lilly/Shionogi) Drug profile Development overview SWOT analysis Product positioning Physicians perceptions of Cymbalta Clinical and commercial attractivenessValdoxan (agomelatine; Servier/Novartis) Drug profile Development overview SWOT analysis Product positioning Physicians perceptions of Valdoxan Clinical and commercial attractivenessAbilify (aripiprazole; Bristol-Myers Squibb/Otsuka) Drug profileProduct Profiles: Depression - Next generation vies for second-line patients 3
  4. 4. Phone: +44 20 8123 2220 http://marketpublishers.com Development overview SWOT analysis Product positioning Physicians perceptions of Abilify Clinical and commercial attractivenessSeroquel XR (quetiapine extended release; AstraZeneca) Drug profile Development overview SWOT analysis Product positioning Physicians perceptions of Seroquel XR Clinical and commercial attractivenessOleptro (trazodone extended release; Labopharm) Drug profile Development overview SWOT analysis Product positioning Clinical and commercial attractivenessOther marketed drugs for depression Remeron (mirtazapine; Merck & Co./Meiji Seika)PIPELINE PRODUCT PROFILESViibryd (vilazodone; Forest) Drug profile Development overview SWOT analysis Satisfaction of unmet needs Clinical and commercial attractivenessLu AA21004 (Lundbeck/Takeda) Drug profile Development overview SWOT analysis Satisfaction of unmet needs Clinical and commercial attractivenessTC-5214 (Targacept/AstraZeneca) Drug profile Development overview SWOT analysis Satisfaction of unmet needs Clinical and commercial attractivenessLevomilnacipran (F2695; Forest/Pierre Fabre) Drug profile Development overview SWOT analysis Satisfaction of unmet needs Clinical and commercial attractivenessEdivoxetine (LY2216684; Eli Lilly) Drug profile Development overview SWOT analysis Satisfaction of unmet needs Clinical and commercial attractivenessVyvanse (lisdexamfetamine; Shire) Drug profileProduct Profiles: Depression - Next generation vies for second-line patients 4
  5. 5. Phone: +44 20 8123 2220 http://marketpublishers.com Development overview SWOT analysis Satisfaction of unmet needs Clinical and commercial attractivenessOther drugs in development for depression CPI-300 (bupropion; IntelGenx) AZD6765 (AstraZeneca) BCI-224 (sabcomeline; BrainCells) BCI-540 (coluracetam; BrainCells/Mitsubishi Tanabe) BCI-952 (melatonin and buspirone; Brain Cells) BMS-820836 (Bristol-Myers Squibb/AMRI) Cariprazine (RGH-118; Forest/Gedeon Richter/Mitsubishi Tanabe) Cimicoxib (UR-8880; Affectis Pharmaceuticals/Palau Pharma) CP-601,927 (Pfizer) EB-1010 (Euthymics Bioscience) GLYX-13 (Naurex) JNJ-26489112 (Johnson & Johnson) Lu AA24530 (Lundbeck/Takeda) OPC-34712 (Otsuka) Orvepitant (GSK823296; GlaxoSmithKline) PNB-01 (pipamperone and citalopram; PharmaNeuroBoost) RG7090 (Roche) SA4503 (cutamesine; M’s Science) Serdaxin (clavulanic acid; Rexahn Pharmaceuticals) SSR125543 (Sanofi) Tasimelteon (VEC-162; Vanda Pharmaceuticals) TriRima (CX157; CeNeRx/Krenitsky Pharmaceuticals)BIBLIOGRAPHYJournal papersWebsitesDatamonitor reportsAPPENDIX A – SURVEY INFORMATIONPhysician research methodology Physician sample breakdownThe survey questionnaire Introduction Section one: diagnosis and patient segmentation Section two: treatment of major depressive disorder Section three: product profiles DemographicsAPPENDIX BPharmaVitae Explorer databaseContributing expertsConferences attendedReport methodologyProduct Profiles: Depression - Next generation vies for second-line patients 5
  6. 6. Phone: +44 20 8123 2220 http://marketpublishers.com I would like to order: Product name: Product Profiles: Depression - Next generation vies for second-line patients Product link: http://marketpublishers.com/r/P9BC1E6E625EN.html Product ID: P9BC1E6E625EN Price: US$ 11,400.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: office@marketpublishers.com Payment To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click BUY NOW button on product page http://marketpublishers.com/r/P9BC1E6E625EN.html To pay by Wire Transfer, please, fill in your contact details in the form below: First name: Last name: E-mail: Company: Address: City: Zip/Post Code: Country: Tel: Fax: Your message: * All fields are required Customer Signature _______________________________________ Please, note that by ordering from MarketPublisher.com you are agreeing to our Terms & Conditions at http://marketpublishers.com/docs/terms_conditions.html To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970Powered by TCPDF (www.tcpdf.org)

×